A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma

BACKGROUND: Several studies showed that gain-of-function somatic mutations affecting the catalytic domain of EGFR in non-small cell lung carcinomas were associated with response to gefitinib and erlotinib, both EGFR-tyrosine kinase inhibitors. In addition, 4% of non-small cell lung carcinomas were s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekaii-Saab, Tanios, Williams, Nita, Plass, Christoph, Calero, Miguel Villalona, Eng, Charis
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1712353/
https://www.ncbi.nlm.nih.gov/pubmed/17150109
http://dx.doi.org/10.1186/1471-2407-6-278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1712353/
https://www.ncbi.nlm.nih.gov/pubmed/17150109
http://dx.doi.org/10.1186/1471-2407-6-278

Ejemplares similares